- Medicine - 08:00 Novartis real- world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
- Environment - Apr 21 Earth day: Imperial event brings together experts to tackle air pollution
- Medicine - Apr 21 Yale experts offer thoughts on ‘Science Under Siege’
- Life Sciences - Apr 21 NIH Awards Team $7 Million for Autism Genetics Research
- Medicine - Apr 21 Senior salsa brings home the power of staying active
- Medicine - Apr 21 Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
- Medicine - Apr 21 EPFL non- profit iM4TB awarded $2.45m for anti-TB drug clinical trials
- Medicine - Apr 21 US Defense supports UQ breast cancer research
- Medicine - Apr 20 How gut bacteria change cancer drug activity
- Life Sciences - Apr 20 Brain’s "hand area" used by other body parts in people born with one hand
- Medicine - Apr 20 What exactly does ‘healthy’ mean when it comes to food?
- Medicine - Apr 20 Centres for the UK Dementia Research Institute announced
- Media - Apr 20 More prime- time ads could kick drunken driving to the curb
- Medicine - Apr 20 Imperial wins bid to host new UK Dementia Research Institute centre
- Medicine - Apr 20 Protection for the gut barrier
- Medicine - Apr 20 Sensor- Equipped Glove Could Help Doctors Take Guesswork Out of Measuring Spasticity
Developing therapeutic peptides from scorpion venom
Canadian health and wellness company PreveCeutical Medical Inc. (PMI) has signed a research and option agreement with UniQuest , The University of Queensland’s main commercialisation company, to develop stabilised natural and synthetic peptides from scorpion venom for immune-boosting applications.
PMI has an interest in the preventative health sector and is developing products derived from Caribbean blue scorpion venom for the nutraceutical and pharmaceutical market.
This includes the CellB9 Immune System Booster product, which contains peptides that are obtained from the Caribbean blue scorpion.
In collaboration with UniQuest, PMI aims to identify the active peptides that provide immune-boosting and tumor-selective painting properties, develop synthetic versions of the active peptides and ultimately identify other therapeutic applications.
UniQuest CEO Dr Dean Moss said the project was based on the research of Dr Harendra (Harry) Parekh , of UQ School of Pharmacy, who will be collaborating with PMI.
“UQ’s School of Pharmacy has unique intellectual property in stabilising therapeutic peptides and is in a position to add value by extending PreveCeutical’s product line,” Dr Moss said.
“This agreement exemplifies the quality of UQ’s intellectual property and the willingness of its researchers to engage globally with industry to develop new products through university-industry collaborations.”
PMI Chairman and Chief Executive Officer Stephen Van Deventer said working with UniQuest and UQ presented unique opportunities to develop products that promoted health and wellness.
“Wellness products developed from scorpion venom-derived natural and synthetic peptides have the potential to be applied across a number of therapeutic applications including boosting the immune system,” Mr Van Deventer said.
The agreement provides PMI with an option to negotiate for a license to use UniQuest’s intellectual property for the commercialisation of blue scorpion venom-derived products.
Last job offers
- Medicine/Pharmacology - 18.4
Professeur-e ordinaire ou associé-e, médecin-chef-fe du service de médecine interne de réhabilitation...
- Medicine/Pharmacology - 15.4
Chargé-e de cours à 40% dans le domaine neuro-musculaire
- Medicine/Pharmacology - 21.3
Dozentin / Dozenten für Pharmakologie und Pharmatechnologie mit Fachgruppenleitung
- Medicine/Pharmacology - 15.3
Professeur-e ordinaire ou associé-e, médecin adjoint-e agrégé-e
- Medicine/Pharmacology - 21.4
Professor of Internal Medicine of Companion Animals (0.8 - 1.0 FTE)
- Medicine/Pharmacology - 20.4
Postdoc in mental health
- Medicine/Pharmacology - 21.4
Professur (W2) auf Zeit (6 Jahre / tenure track) für Kardiovaskulären Metabolismus
- Medicine/Pharmacology - 11.4
Universitätsprofessur für Gesundheitsökonomie